Target intelligence / Profile preview

Patatin-like phospholipase domain-containing protein 2 (PNPLA2) (PNPLA2)

Target
PNPLA2
Molecular classification
Receptor, Enzyme
01

Overview

Patatin-like phospholipase domain-containing protein 2 (PNPLA2), commonly referred to as the Pigment Epithelium-Derived Factor Receptor (PEDF-R), is a key transmembrane protein expressed on various ocular tissues, including limbal stem cells (Notari et al., 2006, J Biol Chem). It serves as the primary mediator for the biological actions of Pigment Epithelium-Derived Factor (PEDF), a potent neurotrophic and anti-angiogenic glycoprotein (Subramanian et al., 2013, Prog Retin Eye Res). Upon binding PEDF, the receptor's intrinsic phospholipase A2 activity is activated, leading to the release of signaling molecules that promote the self-renewal and survival of limbal stem cells while inhibiting apoptosis (Ho et al., 2015, Stem Cells). This interaction is vital for maintaining the corneal epithelial barrier and the transparency of the cornea by preventing neovascularization (He et al., 2015, Invest Ophthalmol Vis Sci). In the context of disease, a deficiency in PEDF or its receptor signaling is associated with limbal stem cell deficiency and pathological blood vessel growth in the eye. Therapeutic strategies targeting PEDF-R primarily involve the use of PEDF-mimetic peptides designed to stimulate the receptor's regenerative and protective pathways. However, because PNPLA2 is also the rate-limiting enzyme in systemic triglyceride hydrolysis (as ATGL), drug development must account for potential metabolic side effects (Zimmermann et al., 2004, Science).

Other names
Pigment epithelium-derived factor receptorPEDF-RAdipose triglyceride lipaseATGLDesnutrinCalcium-independent phospholipase A2 zetaiPLA2-zetaTTS-2.2
02

Mechanism of action

Agonism of the PEDF receptor to trigger phospholipase A2 activity and downstream pro-survival signaling pathways like MAPK/ERK.

03

Biological functions

Signal transductionCell proliferationLipid metabolismStem cell maintenanceAngiogenesis inhibitionApoptosis regulation
04

Disease associations

Limbal stem cell deficiencyCorneal neovascularizationRetinal degenerationInflammationMacular degeneration
05

Safety considerations

Off-target effects on systemic lipid metabolism (ATGL function)Potential for excessive epithelial hyperplasiaInflammatory response in ocular tissues
06

Interacting drugs

PEDF-derived 44-mer peptide

2 more in the full profile.

07

Biomarkers

PNPLA2 expressionp63 alphaABCG2Cytokeratin 14Corneal transparency

Beyond the preview

Go deeper on Patatin-like phospholipase domain-containing protein 2 (PNPLA2) (PNPLA2).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Patatin-like phospholipase domain-containing protein 2 (PNPLA2) (PNPLA2).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call